Cantargia AB (publ)

Cantargia AB (publ) is a Sweden-based biotechnology company specializing in the development of antibody therapeutics for cancer treatment. Its primary focus is on targeting the Interleukin-1 receptor accessory protein (IL1RAP), a cell-surface receptor on malignant stem cells, to eradicate leukemia and other serious cancers. The lead product candidate, CAN04 (nadunolimab), addresses non-small cell lung cancer and pancreatic cancer, while the CAN10 project diversifies the portfolio into complementary disease segments. Headquartered in Lund with 23 employees, Cantargia AB operates in the healthcare sector, particularly biotechnology and medical research, without current revenue generation as it advances clinical programs. Incorporated in 2009 and public since 2015, the company holds a market capitalization around SEK 692 million, reflecting its role in innovative oncology therapies amid high research and development demands. Leadership includes CEO Göran Forsberg and a team of experienced executives and directors driving antibody-based innovations for life-threatening diseases.